	medRxiv preprint doi: https://doi.org/10.1101/2024.07.10.24310021; this version posted July 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.							
1	Clinical Pilot of Bacterial Transcriptional Profiling as a Combined Genotypic and Phenotypic Antimicrobial							
2	Susceptibility Test							
3								
4	Young EL ¹ *, Roach DJ ^{1,2} *, Martinsen MA ¹ , McGrath GEG ⁴ , Holbrook NR ⁴ , Cho HE ⁴ , Seyoum EY ^{1,5} , Pierce							
5	VM ^{4,6} , and Bhattacharyya RP ^{1,3}							
6	* Co-first							
7	1. The Broad Institute of MIT and Harvard, Boston, MA, USA							
8	2. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA							
9	3. Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA							
10 11 12	4. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA							
	5. Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA							
13	6. Current address: Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA							
14 15 16 17 18 19 20 21	Corresponding Author Roby P. Bhattacharyya, MD, PhD Division of Infectious Diseases Massachusetts General Hospital 55 Fruit St Boston MA 02114 rbhatt@broadinstitute.org							
22 23	Brief Summary: Exposure to antibiotics causes differential transcriptional signatures in susceptible vs.							
24	resistant bacteria. These differences can be leveraged to rapidly predict resistance profiles of Escherichia coli							
25	and Klebsiella pneumoniae in clinical positive blood cultures.							
26								
27 28	Running Title: Transcriptional antimicrobial susceptibility testing pilot							

30 ABSTRACT

31 Antimicrobial resistance is a growing health threat, but standard methods for determining antibiotic susceptibility are slow and can delay optimal treatment, which is especially consequential in severe infections 32 such as bacteremia. Novel approaches for rapid susceptibility profiling have emerged that characterize either 33 34 bacterial response to antibiotics (phenotype) or detect specific resistance genes (genotype). GoPhAST-R is a novel assay, performed directly on positive blood cultures, that integrates rapid transcriptional response 35 profiling with detection of key resistance gene transcripts, thereby providing simultaneous data on both 36 37 phenotype and genotype. Here, we performed the first clinical pilot of GoPhAST-R on 42 positive blood cultures: 26 growing Escherichia coli, 15 growing Klebsiella pneumoniae, and 1 with both. An aliguot of each 38 39 positive blood culture was exposed to 9 different antibiotics, lysed, then underwent rapid transcriptional 40 profiling on the NanoString® platform: results were analyzed using an in-house susceptibility classification algorithm. GoPhAST-R achieved 95% overall agreement with standard antimicrobial susceptibility testing 41 methods, with the highest agreement for beta-lactams (98%) and the lowest for fluoroguinolones (88%). 42 43 Epidemic resistance genes including the extended spectrum beta-lactamase blacTX-M-15 and the carbapenemase bl_{KPC} were also detected within the population. This study demonstrates the clinical feasibility 44 of using transcriptional response profiling for rapid resistance determination, although further validation with 45 larger and more diverse bacterial populations will be essential in future work. GoPhAST-R represents a 46 47 promising new approach for rapid and comprehensive antibiotic susceptibility testing in clinical settings.

48

49 **INTRODUCTION**

Infections due to antimicrobial resistant (AMR) bacteria are a major cause of global mortality, accounting for 1.27 million deaths in 2019 alone¹, and result in increased length of hospital stays², higher healthcare costs³, and higher mortality². Delays in appropriate antimicrobial therapy, often due to bacterial resistance to empiric antibiotic selection, directly correlate with increased in-hospital mortality^{4,5}. This can push clinicians toward excessively broad spectrum therapies that may result in worse patient outcomes⁶ and the development of resistance⁷, which underscores the broad potential benefits of rapid antimicrobial susceptibility testing (AST)^{8,9,10}.

57

58 The gold standard for AST involves growing isolates in the presence of an antibiotic to determine the lowest concentration that inhibits bacterial growth¹¹. While reliable, growth-based AST can be time-consuming, taking 59 up to 72 hours from the time of sample collection to the final susceptibility profile. A growing number of 60 61 alternative, rapid AST methods address this challenge in two broad ways: genotypic and phenotypic assays. 62 Genotypic approaches directly identify specific genes or mutations known to confer resistance. This approach 63 relies on detecting a limited subset of genes, however, and so is unable to detect novel or complex resistance mechanisms, especially in gram-negative pathogens¹². Phenotypic assays, conversely, assess bacterial 64 response to antibiotics based on different cellular properties, such as growth¹³, metabolic activity¹⁴, or bacterial 65 motility^{15,16}. Although generally applicable across resistance mechanisms, this approach does not provide 66 information about bacterial genotypes, potentially omitting key data that could inform antibiotic selection¹⁷ and 67 epidemiologic inquiries^{18,19}. 68

69

In recent years, our group developed a method that combines both genotypic and phenotypic information into a single, rapid AST assay termed <u>Genotypic and Ph</u>enotypic <u>AST</u> through <u>RNA</u> detection (Go-PhAST-R)²⁰. Go-PhAST-R uses NanoString® RNA hybridization chemistry²¹ to quantify multiple bacterial transcripts from crude lysate samples and infer resistance patterns. To do so, it leverages the marked differences in gene expression profiles of susceptible isolates compared to species-matched resistant isolates when exposed to antibiotics: resistant isolates are relatively unperturbed, whereas susceptible isolates, physiologically distressed and dying

76 or growth-arrested, demonstrate large transcriptional changes in response to the antibiotic. We previously 77 showed that a small subset of genes undergo large, predictable expression changes upon exposure to a class of antibiotics²². such that the change in expression of these marker genes reflects phenotypic antibiotic 78 79 susceptibility, independent of resistance mechanism. Using this principle, we designed and validated GoPhAST-R probesets to classify susceptibility of Escherichia coli and Klebsiella pneumoniae to 80 aminoglycosides, fluoroquinolones, and beta-lactams²². Additionally, transcripts from high-risk resistance 81 genes, such as extended spectrum beta-lactamases (ESBLs) and carbapenemases, were simultaneously 82 83 interrogated to identify high-risk genotypes of epidemiologic relevance. In prior work done on blood cultures spiked with laboratory strains with pre-specified resistance patterns, Go-PhAST-R achieved 94-99% accuracy, 84 85 required minimal technical expertise and hands-on time, and returned results as soon as <4 hours after a positive blood culture²⁰. 86 87

In this work, we implement this assay in a clinical setting for the first time, testing 42 blood cultures that grew *E. coli* or *K. pneumoniae* from the clinical microbiology laboratory at Massachusetts General Hospital (MGH).
Transcriptional responses to antibiotic exposure clustered by susceptibility classification (i.e., susceptible
strains and resistant strains exhibited distinct transcriptional responses), with 95% overall categorical
agreement to standard clinical testing. These results are the first demonstration in a clinical setting of an assay
based on the new paradigm of using bacterial transcriptional responses to predict antibiotic susceptibility.

94

95 METHODS

96 Bacterial Collection and Routine Culture Methods

97 A total of 66 unique positive blood cultures with gram-negative rods on Gram stain were collected; only one 98 sample per patient was included. At the time a blood culture bottle signaled positive on the BACTEC FX 99 system (Becton Dickinson, Sparks, MD), a 1mL aliquot was taken for processing as below. The remainder was 100 carried forward for routine clinical processing, including subculture to solid media followed by colony 101 identification via MALDI-TOF mass spectrometry (VITEK MS, version 3.2 in vitro diagnostic Knowledge Base, 102 bioMérieux, Durham, NC) and antimicrobial susceptibility testing (AST) using the VITEK 2 AST-GN81 Gram 103 Negative Susceptibility Card (bioMérieux), clinically validated for use with Clinical and Laboratory Standards

Institute (CLSI) breakpoints published in M100-Ed31²³. Aztreonam and cefazolin were tested by the CLSI disk
 diffusion method²⁴ due to limitations of the VITEK 2 AST card; aztreonam was not included on the card, and
 the lowest concentration of cefazolin did not permit susceptible and intermediate minimum inhibitory
 concentrations (MICs) to be distinguished. Cefazolin susceptibility was further tested by broth microdilution²⁵ in

- 108 the research laboratory.
- 109

110 Antibiotic treatment

As in prior implementations of GoPhAST-R²⁰, a 1mL aliquot of each positive blood culture was first spun down 111 at 100g for 10min to pellet red blood cells. The supernatant was then spun at 16,000g for 3min to pellet 112 bacteria. The supernatant was removed, and the bacterial pellet resuspended in cation-adjusted Mueller-113 Hinton broth (CAMHB. ThermoFisher Scientific, Lenexa, KS) to a final volume of 500uL. Separate 45ul aliquots 114 were added to pre-diluted 5 uL aliquots of cefazolin (CFZ), ceftriaxone (CRO), aztreonam (ATM), piperacillin-115 tazobactam (TZP), cefepime (FEP), ertapenem (ETP), meropenem (MEM), ciprofloxacin (CIP), levofloxacin 116 (LVX), or gentamicin (GEN) to expose at CLSI breakpoint concentrations²³ (Table S1). Bacteria were exposed 117 at 37° C to each non-beta-lactam antibiotic for 60min, or 120min for beta-lactams given the slower response 118 for this class²². In prior work, we found that the beta-lactam inoculum effect²⁶ required exposure at standard 119 CLSI-recommended inocula in order for the transcriptional response to reflect susceptibility²². Thus, beta-120 lactam treated samples and one untreated control were diluted 1:100 (targeting 5e5 cfu/mL) prior to incubation 121 and plated at the time of antibiotic exposure to enumerate colony forming units to confirm. To assess baseline 122 transcriptional signatures, two aliguots of each sample were each added to 5ul of CAMHB without antibiotics. 123 and these untreated cultures were removed at either 60min (for comparison with aminoglycosides and 124 fluoroquinolones) or 120min (for comparison with beta-lactams). Lysis buffer was added, and the samples 125 were flash-frozen and stored at -80°C for subsequent batch processing. 126

127

128 Lysis and Hybridization

Samples for which routine clinical testing identified *E. coli* or *K. pneumoniae* were thawed and lysed on the MP
 FastPrep[™] bead beater²². Crude lysates were carried forward on the NanoString[®] platform per manufacturer's
 protocols. RNA probe sets were designed as per prior work²⁰. Samples were hybridized for 1 hour as per our

- prior protocol^{20,22}, except for those treated with beta-lactams, which were hybridized for 16 hours to ensure
- 133 sufficient signal from the lower initial inoculum.
- 134

135 Quantification of Transcriptional Response and Genotyping

Data were partitioned by each antibiotic and species combination. Raw transcript counts were first normalized 136 to NanoString® spike-in controls per manufacturer's protocol, and then to housekeeping genes selected to 137 have consistent expression to control for bacterial cellular density, as previously described²⁰. To assess 138 transcriptional response, we next calculated log₂ fold change in normalized transcript counts between treated 139 and untreated samples. To characterize resistance genotypes, probes were measured that targeted conserved 140 regions of the carbapenemase genes *bla*_{KPC}, *bla*_{NDM}, *bla*_{VIM}, *bla*_{IMP}, and *bla*_{OXA-48} and the extended spectrum 141 beta-lactamase gene *bla*_{CTX-M-15}²⁰. If any of these probes were detected above background, the gene was 142 considered present. 143

144

145 Model Construction and Resistance Prediction

To represent the entire transcriptional response profiles in a single quantitative metric, we used a method of 146 one-dimensional projection called squared projected distance (SPD)²⁷ to summarize each sample's 147 responsiveness in comparison to reference data from samples with known MICs. In brief, centroids 148 representing the average transcriptional response of known susceptible and resistant isolates are computed for 149 each antibiotic and species combination from highly susceptible and resistant strains from a reference set²². 150 Distance from the susceptible centroid is calculated for each new transcriptional profile and scaled by the 151 distance between the sensitive and resistant centroids; thus, an SPD of 0 represents a response similar to that 152 153 of the control set of susceptible strains, whereas an SPD of 1 represents a resistant-like response.

154

We used support vector machine (SVM) modeling for each species and drug class as a tool to report the degree to which our susceptible and resistant isolates separate from each other by their SPD values. SVM is an unbiased, algorithmic method of identifying natural separation in data that minimizes overfitting by maximizing distance between boundaries and each class of data²⁸. We implemented SVM models using the e1071 package²⁹ on a dataset that included both the current samples as well as a larger collection with a

higher proportion of resistant isolates from prior work²², using clinical susceptibility classifications as "ground 160 truth". To minimize the most clinically important discrepant classifications, we set the model to penalize very 161 major discrepancies (VMDs) (R strain misclassified as S) twice as much as major discrepancies (S strain 162 misclassified as R). For the genotypic portion of the assay, we incorporated whether resistance gene of a given 163 class were detected, and if so, we considered the isolate to be resistant to the relevant antibiotic regardless of 164 the SVM prediction (Supplemental Fig. S1). While the assay was run for cefazolin, the results were excluded 165 from the final SVM model because (a) the CLSI breakpoint concentration falls within the MIC distribution of 166 wild-type strains³⁰. which in practice leads to classification challenges, exemplified in our collection by frequent 167 discordance between susceptible and intermediate classifications for samples tested by disk diffusion and 168 broth microdilution methods (Supplemental Fig. S2); and (b) cefazolin is not a recommended first-line therapy 169 for gram-negative bacteremia, which was the focus of this study. 170

171

172 **RESULTS**

173 Bacterial collection and clinical AST determination

A total of 66 positive blood cultures with gram-negative rods on Gram stain were exposed in real-time in the 174 clinical microbiology laboratory to the selected antimicrobials (Supplemental Table S1; see Methods). Of these 175 66 cultures, 26 were subsequently identified as E. coli and 15 as K. pneumoniae, for which we had previously 176 designed probes for transcriptional susceptibility testing to beta-lactams, fluoroguinolones, and 177 aminoglycosides²². In one case (sample 17), a blood culture was identified as having both species and was 178 carried forward. The other 24 samples included species for which we do not have transcriptional probes and 179 thus were not processed further. Routine clinical testing of these isolates found relatively low levels of 180 resistance, with the highest rate of non-susceptibility found for ciprofloxacin at 26% (7/27) in E. coli and 19% 181 (3/16) in K. pneumoniae, and the lowest rate seen for the carbapenems at 0% (0/27) and 6.3% (1/16) 182 respectively (Table 1). While intermediate MICs were rare in the collection, we found 4 instances of 183 intermediate MICs to levofloxacin in E. coli and 2 in K. pneumoniae. 184 185

186 Transcriptional Response to Drug Treatment and Resistance Genotyping

To assess susceptibility from transcriptional profile, we measured levels of 10-13 transcripts per each drug 187 class and calculated change in normalized expression between treated and untreated states²⁰ (Figure 1A). 188 While strain variation is present across drug treatments, E. coli and K. pneumoniae samples predominantly 189 demonstrated one of two transcriptional profiles: susceptible isolates exhibited large perturbations in 190 transcriptional responses upon antibiotic exposure, whereas resistant isolates demonstrated very little to no 191 perturbation. When grouped by drug and species, transcripts from susceptible isolates were perturbed by an 192 absolute log₂-fold value of 1.0 to 4.0 averaged across all responsive genes, with most drug-species pairs 193 falling between 1.5 and 3.0; while for resistant samples these values ranged from 0.2 to 1.8, with all but one 194 falling below 0.9 (a carbapenem-resistant K. pneumoniae, see below) (Figure 1B). While uncommon, samples 195 with intermediate MICs showed a wider average perturbation range of between 0.2 and 3.8 absolute log₂-fold 196 197 change. 198

After condensing probe responses into squared projected distance $(SPD)^{27}$ (Figure 2A and 2B, Supplemental Fig. S3), a metric we previously devised to represent transcriptional response to antibiotic (see Methods), samples categorized as susceptible by clinical AST had a mean SPD value of 0.027 (median 0.0, interquartile range [IQR] ±0.09), while resistant samples had a mean SPD of 0.975 (median 1.0, IQR ±0.31). Samples with intermediate susceptibilities had a mean of 0.23 (median 0.1, IQR ±0.184) (Figure 2C).

204

In total, our genotypic probes detected $bla_{CTX-M-15}$ in 2 *E. coli* isolates and 3 *K. pneumoniae* isolates, and a single carbapenemase gene, a bla_{KPC} found in sample 48, a *K. pneumoniae* that displayed a transcriptional response to both ertapenem and meropenem despite harboring this resistance gene (**Supplementary Fig S4**).

209 Susceptibility Predictions

We used a support vector machine (SVM) model to find the natural separation in the SPD values that best delineated susceptible and non-susceptible isolates (per clinical AST) and incorporated this into an algorithm for resistance classification (see Methods and **Supplementary Fig. S1**). We had an overall categorical agreement of 95% (368/387 pairwise drug comparisons) with standard susceptibility profiling (**Figure 3**). In total, there was a 5% very major discrepancy (VMD) rate (2/42 resistant isolates), a 2% major discrepancy

(MD) rate (7/334 susceptible), and a 3% minor discrepancy rate (Supplementary Table S2). The bestperforming grouping was the beta-lactam class in *E. coli*, with 99% overall categorical agreement and zero
VMDs. The worst performing combination was in the fluoroquinolone class, with categorical agreement rates of
89% for *E. coli* and 88% for *K. pneumoniae* (Supplementary Table S2), and VMDs of 8% and 20%,
respectively, representing one VMD in each species, with 12/13 correct resistance predictions for *E. coli* and
4/5 correct predictions for *K. pneumoniae*. Both misclassifications were in ciprofloxacin for isolates with VITEK
2 MICs at the resistant clinical breakpoint (Figure S3).

222

223 Unexpectedly, we obtained one mixed culture of *E. coli* and *K. pneumoniae* during our collection (sample 17).

224 Since each NanoString probe is species-specific in its reactivity pattern, we reasoned that we might see

species-specific transcriptional responses for each species without subculture, so we carried the sample

through gene expression profiling and analysis, using both *E. coli* and *K. pneumoniae* probesets for this

sample (Figure S3, samples 17ec and 17kp). 18 of 20 SPD-based predictions for these two strains were in

228 categorical agreement with clinical AST testing, with discrepancies only in fluoroquinolone susceptibility of the

229 E. coli strain (one major discrepancy and one minor discrepancy for ciprofloxacin and levofloxacin,

respectively; Supplementary Table S3). When this isolate was regrown and tested in laboratory monoculture,
it demonstrated the expected susceptible transcription profile, with its SPD dropping from 0.93 to 0.15 (Figure
S5). The *K. pneumoniae* in the mixed culture, by contrast, had perfect agreement with clinical AST results

performed on the subcultured isolate (**Supplementary Table S3**).

234

235 **DISCUSSION**

Here, we present the first pilot implementation of a transcription-based AST assay performed directly on positive blood cultures from clinical samples. This novel approach utilizes a single platform to concurrently assess bacterial phenotypic response to antimicrobials and identify high-risk AMR resistance genes in an integrated assay, culminating in a susceptibility prediction. The assay demonstrated strong overall concordance with routine AST methods, with some variation observed across antibiotic classes. Notably, betalactam antibiotics achieved 98% categorical agreement with standard clinical testing for six commonly used beta-lactams across both species and had no very major discrepancies (VMDs). Gentamicin also exhibited no

VMDs in either species. However, two *E. coli* isolates classified as susceptible by standard testing were
misclassified as resistant by the assay (major discrepancies) and one intermediate *K. pneumoniae* isolate was
misclassified as resistant (minor discrepancy). Fluoroquinolones displayed the least favorable performance,
with VMD rates of 8% (1/13) and 20% (1/5) in *E. coli* and *K. pneumoniae*, respectively, which represented the

247 only VMDs across our entire sample set.

248

We examined each case in which the transcriptional response differed from expectation based on routine 249 clinical susceptibility classification. In total, we observed four instances of resistant samples transcriptionally 250 responding to treatment, which generally occurred in samples with MICs near the breakpoints (Supplemental 251 Fig. S3). However, in two of these instances, the correct susceptibility prediction was made through genotypic 252 detection. In these strain and antibiotic pairings, the K. pneumoniae isolate expressing blakPC (#48) showed 253 considerable perturbations in the presence of both meropenem and ertapenem. While detecting $bl_{\alpha_{\rm KPC}}$ is 254 sufficient to eliminate carbapenem drugs as treatment options³¹, it has been noted previously that *bla*_{KPC}-255 producing strains may display low MICs to carbapenems³², especially at low inocula²⁶. In a different case, one 256 blood culture (#17) was polymicrobial, growing both E. coli and K. pneumoniae. While the K. pneumoniae 257 behaved as expected, the E. coli was susceptible to ciprofloxacin by MIC testing but did not demonstrate a 258 strong transcriptional response, leading to a miscall as a resistant isolate by our model. The transcriptional 259 response of this sample, however, looks gualitatively different than the "true" resistant profiles (Supplemental 260 Fig. S3, ciprofloxacin panel, sample 17ec). On examination of the raw data from this sample, sample 17ec had 261 low total transcript counts, likely introducing noise into the transcriptional signature, perhaps because E. coli 262 was present at lower abundance than usual when the bottle signaled positive. As we have not previously 263 included polymicrobial samples in the assay, further dedicated exploration will be needed to determine the 264 optimal method for handling such samples. However, the ability in principle to simultaneously profile responses 265 to multiple strains is a potentially appealing feature of this assay, as we observed 90% categorical agreement 266 with standard AST testing across 20 phenotypic tests for these two isolates. The majority of the remaining 267 268 errors were minor discrepancies in samples with MICs near CLSI breakpoints (Fig S3), which are inherently challenging classifications even in gold-standard AST methods^{33,34}. 269

Our assay also captured genotypic information regarding the presence of key beta-lactamases, adding several 271 useful features beyond phenotypic testing alone. First, as outbreaks of carbapenem-resistant bacteria may be 272 caused by the spread of epidemic beta-lactamases¹⁸, knowledge about their presence has implications for 273 infection control practices³⁵. Second, a growing number of clinical decisions are determined by bacterial 274 genotype. Current IDSA guidelines, for example, recommend carbapenems as first-line therapy for complicated 275 infections caused by ESBL-producing organisms¹⁷. Finally, the emergence of novel beta-lactamase inhibitors 276 with specificities for different carbapenemases underscores a role for gene identification to guide optimal 277 antibiotic selection. Ceftazidime-avibactam, for instance, is effective against blakPC and blacxA-48 278 carbapenemase-producing isolates but has no activity against metallo-beta-lactamases such as *bla*NDM³⁶. As 279 additional inhibitors to specific beta-lactamases are developed, the utility of defining genotype and phenotype 280 together will likely grow in importance. 281

282

One limitation of our study is the low rates of bloodstream infections from resistant organisms within the cohort, 283 resulting in a low number available for testing. However, we previously validated the assay on spike-in samples 284 overrepresented for resistant isolates^{20,22}. Second, the greatest discordance compared to standard testing 285 occurred in those samples with MIC values near the clinical breakpoints, especially in the fluoroquinolone 286 class. The inclusion of additional samples near breakpoints will be key to improving performance for this 287 subset of isolates. Third, as CLSI clinical breakpoints evolve, the models would need to be retrained on 288 updated guidelines to maintain the greatest accuracy. Fourth, our comparator method was not the reference 289 290 standard of broth microdilution, but rather VITEK 2 (and disk diffusion in select cases), due to pragmatic considerations; however, this comparator reflects standard practices in many clinical microbiology laboratories, 291 including our own. Most importantly, in this study we used SVM modeling to separate SPD values, and in order 292 to have a sufficient number of resistant samples for model training, we combined data from prior work²² with 293 the current population. This approach was necessary due to the low total numbers of resistant organisms, but 294 as a result we do not have a fully independent validation set. We previously used a more sophisticated strategy 295 using machine learning to train random forest models on the responses of each individual probe to create a 296 robust classifier for meropenem, ciprofloxacin, and gentamicin susceptibility²⁰. However, this approach requires 297 larger training datasets, including a sizeable number of resistant isolates, to rigorously train and independently 298 validate in a multistep process. Because each individual antibiotic within a class elicits a distinct magnitude of 299

300	transcriptional response in each species (Supplemental Fig. S2), we could not use this original model without
301	testing and retraining on hundreds of isolates, which was outside the scope of the current study. This additional
302	training will be critical prior to clinical implementation and should improve classification accuracy. Finally, due to
303	limited sensitivity of the stock NanoString nCounter Sprint detector system in our laboratory, we required a 16-
304	hour hybridization time to detect signal from the lower inoculum samples used for beta-lactam testing. Pilot
305	instruments under development offer improved RNA detection sensitivity with much shorter hybridization
306	times ²⁰ , which would bring beta-lactam testing times in line with other antibiotics.
307	
308	In summary, in this study we perform the first clinical pilot using a diagnostic testing approach that
309	simultaneously and rapidly detects bacterial phenotypic response to antibiotic exposure as well as epidemic
310	AMR gene content. The synthesis of these complementary paradigms represents a promising step toward the
244	

- next generation of clinical antimicrobial susceptibility testing. While further studies utilizing larger cohorts are
- necessary to refine the predictive algorithm and enhance its robustness, and automation of the process would
- be required before clinical utilization, this work establishes a framework for the continued development and
- 314 ultimate clinical implementation of this novel transcriptional assay.

316 Acknowledgements

- 317 We thank the Massachusetts General Hospital Clinical Microbiology Laboratory for assistance with sample
- 318 collection.
- 319
- 320 Notes
- 321 IRB approval
- 322 Clinical blood culture aliquots were collected under Mass General Brigham Institutional Review Board protocol
- 323 2015P002215.
- 324
- 325 Financial support.
- 326 This work was supported by the Massachusetts General Hospital Pilot Translational Research Grant (to RPB
- and VMP), the Broad Institute NextGen Award (to RPB), the National Institutes of Health (1R01AI153405, to
- RPB), and the John G. Bartlett Fellowship of the Antibiotic Resistance Leadership Group (T32AI007061-44, to
- 329 DJR). The funders had no role in study design, data collection and interpretation, or the decision to submit the
- 330 work for publication. The content is solely the responsibility of the authors and does not necessarily represent
- the official views of the National Institutes of Health.
- 332
- 333 Conflicts of Interest.
- 334 The authors declare no conflicts of interest.
- 335
- 336 Data sharing.
- All data generated and the code used for analysis are available on GitHub at
- 338 https://github.com/broadinstitute/Go-PhAST-R_Clinical_Pilot/
- 339

340 **References**:

- Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0
- Falcone M, Tiseo G, Carbonara S, et al. Mortality Attributable to Bloodstream Infections Caused by
 Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy
 (ALARICO Network). *Clin Infect Dis*. 2023;76(12):2059-2069. doi:10.1093/cid/ciad100
- Poudel AN, Zhu S, Cooper N, et al. The economic burden of antibiotic resistance: A systematic review and meta-analysis. *PLOS ONE*. 2023;18(5):e0285170. doi:10.1371/journal.pone.0285170
- Roach DJ, Sridhar S, Oliver E, et al. Clinical and Genomic Characterization of a Cohort of Patients With Klebsiella pneumoniae Bloodstream Infection. *Clin Infect Dis*. Published online August 26, 2023:ciad507. doi:10.1093/cid/ciad507
- 5. Falcone M, Bassetti M, Tiseo G, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. *Crit Care*.
 2020;24:29. doi:10.1186/s13054-020-2742-9
- Webb BJ, Sorensen J, Jephson A, Mecham I, Dean NC. Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study. *Eur Respir J*. 2019;54(1). doi:10.1183/13993003.00057-2019
- Shepherd MJ, Fu T, Harrington NE, et al. Ecological and evolutionary mechanisms driving within-patient emergence of antimicrobial resistance. *Nat Rev Microbiol*. Published online April 30, 2024:1-16.
 doi:10.1038/s41579-024-01041-1
- Peri AM, Chatfield MD, Ling W, Furuya-Kanamori L, Harris PNA, Paterson DL. Rapid diagnostic tests and antimicrobial stewardship programs for the management of bloodstream infection: What is their relative contribution to improving clinical outcomes? A systematic review and network meta-analysis. *Clin Infect Dis*. Published online April 27, 2024:ciae234. doi:10.1093/cid/ciae234
- Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. The Effect of
 Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review
 and Meta-analysis. *Clin Infect Dis.* 2017;64(1):15-23. doi:10.1093/cid/ciw649
- 367 10. Satlin MJ, Chen L, Gomez-Simmonds A, et al. Impact of a Rapid Molecular Test for Klebsiella pneumoniae
 368 Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem 369 Resistant Enterobacterales. *Clin Infect Dis.* 2022;75(12):2066-2075. doi:10.1093/cid/ciac354
- 11. Gajic I, Kabic J, Kekic D, et al. Antimicrobial Susceptibility Testing: A Comprehensive Review of
 Currently Used Methods. *Antibiotics*. 2022;11(4):427. doi:10.3390/antibiotics11040427
- Yee R, Dien Bard J, Simner PJ. The Genotype-to-Phenotype Dilemma: How Should Laboratories Approach
 Discordant Susceptibility Results? *J Clin Microbiol*. 59(6):e00138-20. doi:10.1128/JCM.00138-20
- 13. Zalas-Więcek P, Bogiel T, Gospodarek-Komkowska E. The Accelerate PhenoTM System—A New Tool in Microbiological Diagnostics of Bloodstream Infections: A Pilot Study from Poland. *Pathogens*.
 2022;11(12):1415. doi:10.3390/pathogens11121415
- 14. Chen C, Hong W. Recent Development of Rapid Antimicrobial Susceptibility Testing Methods through
 Metabolic Profiling of Bacteria. *Antibiotics*. 2021;10(3):311. doi:10.3390/antibiotics10030311

379 15. Truong TT, Mongkolrattanothai K, Flores II, Dien Bard J. Evaluation of the Performance and Clinical Impact of a Rapid Phenotypic Susceptibility Testing Method Directly from Positive Blood Culture at a 380 381 Pediatric Hospital. J Clin Microbiol. 2022;60(8):e00122-22. doi:10.1128/jcm.00122-22 16. Kasas S, Malovichko A, Villalba MI, Vela ME, Yantorno O, Willaert RG. Nanomotion Detection-Based 382 Rapid Antibiotic Susceptibility Testing. Antibiotics. 2021;10(3):287. doi:10.3390/antibiotics10030287 383 17. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of 384 America 2022 Guidance on the Treatment of Extended-Spectrum B-lactamase Producing Enterobacterales 385 (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-386 Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis Off Publ Infect Dis Soc Am. 2022;75(2):187-212. 387 388 doi:10.1093/cid/ciac268 18. Patel B, Hopkins KL, Freeman R, Pople D, Brown CS, Robotham JV. Carbapenemase-producing 389 Enterobacterales: a challenge for healthcare now and for the next decade. Infect Prev Pract. 390 2020;2(3):100089. doi:10.1016/j.infpip.2020.100089 391 19. Yamagishi T, Matsui M, Sekizuka T, et al. A prolonged multispecies outbreak of IMP-6 carbapenemase-392 producing Enterobacterales due to horizontal transmission of the IncN plasmid. Sci Rep. 2020;10(1):4139. 393 doi:10.1038/s41598-020-60659-2 394 20. Bhattacharyya RP, Bandyopadhyay N, Ma P, et al. Simultaneous detection of genotype and phenotype 395 enables rapid and accurate antibiotic susceptibility determination. Nat Med. 2019;25(12):1858-1864. 396 397 doi:10.1038/s41591-019-0650-9 21. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-398 coded probe pairs. Nat Biotechnol. 2008;26(3):317-325. doi:10.1038/nbt1385 399 22. Martinsen MA, Jaramillo Cartagena A, Bhattacharyya RP. Core Antibiotic-Induced Transcriptional 400 Signatures Reflect Susceptibility to All Members of an Antibiotic Class. Antimicrob Agents Chemother. 401 2021;65(6):10.1128/aac.02296-20. doi:10.1128/aac.02296-20 402 23. Clinical and Laboratory Standards Institute. CLSI. Performance Standards for Antimicrobial Susceptibility 403 404 Testing. 31st ed. CLSI supplement M100. Published online 2021. 405 24. Clinical and Laboratory Standards Institute. CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests. 13th ed. CLSI standard M02. Wayne, PA: Published online 2018. 406 25. Wiegand I, Hilpert K, Hancock REW. Agar and broth dilution methods to determine the minimal inhibitory 407 concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3(2):163-175. 408 doi:10.1038/nprot.2007.521 409 26. Cartagena AJ, Taylor KL, Smith JT, et al. The carbapenem inoculum effect provides insight into the 410 molecular mechanisms underlying carbapenem resistance in Enterobacterales. Published online October 4, 411 2023:2023.05.23.541813. doi:10.1101/2023.05.23.541813 412 27. Barczak AK, Gomez JE, Kaufmann BB, et al. RNA signatures allow rapid identification of pathogens and 413 antibiotic susceptibilities. Proc Natl Acad Sci. 2012;109(16):6217-6222. doi:10.1073/pnas.1119540109 414 28. Cortes C, Vapnik V. Support-vector networks. Mach Learn. 1995;20(3):273-297. doi:10.1007/BF00994018 415 29. Meyer [aut D, cre, Dimitriadou E, et al. e1071: Misc Functions of the Department of Statistics, Probability 416 Theory Group (Formerly: E1071), TU Wien. Published online December 6, 2023. Accessed April 18, 2024. 417 https://cran.r-project.org/web/packages/e1071/index.html 418

- 419 30. Turnidge JD, on behalf of the Subcommittee on Antimicrobial Susceptibility Testing of the Clinical and Laboratory Standards Institute. Cefazolin and Enterobacteriaceae: Rationale for Revised Susceptibility 420 421 Testing Breakpoints. Clin Infect Dis. 2011;52(7):917-924. doi:10.1093/cid/cir031 422 31. Cui X, Zhang H, Du H. Carbapenemases in Enterobacteriaceae: Detection and Antimicrobial Therapy. Front Microbiol. 2019;10. doi:10.3389/fmicb.2019.01823 423 32. Gagetti P, Pasteran F, Martinez MP, et al. Modeling Meropenem Treatment, Alone and in Combination 424 with Daptomycin, for KPC-Producing Klebsiella pneumoniae Strains with Unusually Low Carbapenem 425 MICs. Antimicrob Agents Chemother. 2016;60(8):5047-5050. doi:10.1128/AAC.00168-16 426 33. Mouton JW, Meletiadis J, Voss A, Turnidge J. Variation of MIC measurements: the contribution of strain 427 and laboratory variability to measurement precision. J Antimicrob Chemother. 2018;73(9):2374-2379. 428 429 doi:10.1093/jac/dky232 34. Simner PJ, Rauch CA, Martin IW, et al. Raising the Bar: Improving Antimicrobial Resistance Detection by 430 Clinical Laboratories by Ensuring Use of Current Breakpoints. Open Forum Infect Dis. 2022;9(3):ofac007. 431 doi:10.1093/ofid/ofac007 432 433 35. Palmore TN, Henderson DK. Managing Transmission of Carbapenem-Resistant Enterobacteriaceae in Healthcare Settings: A View From the Trenches. Clin Infect Dis Off Publ Infect Dis Soc Am. 434 2013;57(11):1593-1599. doi:10.1093/cid/cit531 435 36. Kazmierczak KM, Bradford PA, Stone GG, de Jonge BLM, Sahm DF. In Vitro Activity of Ceftazidime-436 Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the 437 International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 438
- 2012 to 2015. Antimicrob Agents Chemother. 2018;62(12):10.1128/aac.00592-18. doi:10.1128/aac.00592-18
 18



Figure 1. Assay Workflow and Summary of Transcriptional Profiles in Study Population. Transcriptional 442 response to antibiotic exposure differs by susceptibility classification. (A.) Schematic workflow for an individual 443 sample. (B) Clinical isolates show predictable transcriptional response to antibiotic treatment based on 444 445 susceptibility profile. Absolute value of log2 fold-change of all transcript counts of genes targeted by the 446 probeset upon antibiotic exposure averaged across isolates, subset by antibiotic and grouped according to clinical resistance profile (susceptible, intermediate, and resistant) and species (E. coli and K. pneumoniae). 447 Antibiotics are abbreviated as per Table 1 and grouped by class. The color of each bar represents the average 448 log2 fold change in transcript counts, while the height of each bar corresponds to the number of samples with 449 450 that susceptibility profile for each antibiotic.



452

Figure 2: SPD Calculation from Transcriptional Response and Distribution. Transcriptional profile is 453 distilled into a measure of treatment response with SPD, a single-value summary of the transcriptional 454 response across the genes of interest (see Methods). (A-B). Heatmaps of the log2 fold change in 455 456 transcriptional response of each (A) E. coli or (B) K. pneumoniae isolate after exposure to ceftriaxone. Each 457 row corresponds to a different gene of interest, while each column is a different blood culture sample. KPC and 458 CTX-M-15 genotypes are shown above the heatmap, while sample numbers, SPD values, and MICs (µg/mL) 459 are shown below. (C) Box-and-whisker plot of SPD values for each species and antibiotic combination, grouped by clinical susceptibility profile. Antibiotic abbreviations are as listed in Table 1. 460



Figure 3: Predictions of Drug Susceptibility by SVM Modeling and Genotype. SVM thresholds for each drug class and bacterial species are shown by the dotted line. SVM is a model to find the optimal separation between two classes of data (see Methods). Each point corresponds to an SPD value (y-axis) and is shaped according to gene content and colored according to whether the SVM algorithm made the correct resistance assignment. Samples are grouped according to clinical susceptibility classification (x-axis).

467

468

	E. coli			K. pneumoniae		
Antibiotic	S	Ι	R	S	-	R
Ceftriaxone (CRO)	24	0	3	12	0	4
Aztreonam (ATM)	24	1	2	12	0	4
Piperacillin Tazobactam (TZP)	27	0	0	14	1	1
Cefepime (FEP)	25	1	1	14	0	2
Ertapenem (ETP)	27	0	0	15	0	1
Meropenem (MEM)	27	0	0	15	0	1
Ciprofloxacin (CIP)	20	0	7	12	1	3
Levofloxacin (LVX)	17	4	6	12	2	2
Gentamicin (GEN)	23	0	4	14	1	1

469

470 471 Table 1: Isolates tabulated by their susceptibility profiles per standard testing in the clinical microbiology

laboratory.